公开(公告)号：US09696307B2

公开(公告)日：2017-07-04

申请号：US14603002

申请日：2015-01-22

申请人： Biogen Idec MA Inc.

发明人： Leonid Gorelik ,  Alexey Lugovskoy

IPC分类号： G01N33/569 ,  C07K16/08 ,  G01N33/53

CPC分类号： G01N33/56983 ,  C07K16/081 ,  C07K2317/33 ,  G01N2333/025 ,  G01N2469/20 ,  G01N2800/28 ,  G01N2800/50 ,  G01N2800/52

摘要： Methods and compositions for determining whether a subject is at risk for PML, including subjects being treated with immunosuppressants, by determining whether the subject harbors a JCV variant with reduced binding for sialic acid relative to a normal JCV, are presented. Furthermore, combinations of JCV-VP1 sequence variations that are associated with PML and that can be used as a basis of an assay for identifying subjects susceptible to PML, subjects with PML (e.g., early stage PML), or subjects at risk of developing PML in response to an immunosuppressive treatment are provided.

公开(公告)号：US20160200823A1

公开(公告)日：2016-07-14

申请号：US15084088

申请日：2016-03-29

申请人： UCB PHARMA S.A. ,  BIOGEN IDEC MA INC.

发明人： LINDA C. BURKLY ,  JANINE L. FERRANT-ORGETTAS ,  ELLEN A. GARBER ,  YEN-MING HSU ,  LIHE SU ,  FREDERICK R. TAYLOR ,  RALPH ADAMS ,  DEREK THOMAS BROWN ,  ANDREW GEORGE POPPLEWELL ,  MARTYN KIM ROBINSON ,  ANTHONY SHOCK ,  KERRY LOUISE TYSON

IPC分类号： C07K16/28 ,  A61K45/06 ,  A61K39/395

CPC分类号： C07K16/2875 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/71 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92

摘要： This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.

公开(公告)号：US09321840B2

公开(公告)日：2016-04-26

申请号：US14309118

申请日：2014-06-19

申请人： UCB PHARMA S.A. ,  BIOGEN IDEC MA INC.

发明人： Linda C. Burkly ,  Janine L. Ferrant-Orgettas ,  Ellen A. Garber ,  Yen-Ming Hsu ,  Lihe Su ,  Frederick R. Taylor ,  Ralph Adams ,  Derek Thomas Brown ,  Andrew George Popplewell ,  Martyn Kim Robinson ,  Anthony Shock ,  Kerry Louise Tyson

IPC分类号： C07K16/28 ,  A61K39/00

CPC分类号： C07K16/2875 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/71 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92

摘要： This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.

摘要翻译： 本发明提供特异性结合CD154（CD40L）蛋白的结合蛋白，包括抗体，抗体衍生物和抗体片段。 本发明还提供了嵌合，人源化或完全人抗体，抗体衍生物或抗体片段，其特异性结合包含根据SEQ ID NO：1的可变重链序列的人源化Fab片段的表位，并包含可变轻链序列 根据SEQ ID NO：2特异性结合。 本发明的CD154结合蛋白可以引起相对于第二抗-CD154抗体降低的效应子功能。 本发明的CD154结合蛋白可用于诊断和治疗方法，例如治疗和预防包括由CD154-CD40相互作用介导的不期望的免疫应答的疾病。

公开(公告)号：US20150299123A1

公开(公告)日：2015-10-22

申请号：US14443944

申请日：2013-11-20

申请人： BIOGEN IDEC MA INC.

发明人： Hairuo Peng ,  Zhili Xin ,  Lihong Sun ,  Timothy Chan ,  Gnanasambandam Kumaravel ,  Arthur G. Taveras

IPC分类号： C07D211/62 ,  C07C229/14 ,  A61K31/197 ,  C07D207/16 ,  A61K31/40 ,  C07C229/48 ,  A61K31/196 ,  C07D205/04 ,  A61K31/397 ,  C07D211/34 ,  C07C229/50 ,  C07D211/46 ,  C07D401/10 ,  A61K31/4545 ,  C07D237/14 ,  A61K31/50 ,  C07D239/34 ,  A61K31/505 ,  C07D417/04 ,  A61K31/427 ,  A61K45/06 ,  A61K31/445

CPC分类号： C07D211/62 ,  A61K31/196 ,  A61K31/197 ,  A61K31/397 ,  A61K31/40 ,  A61K31/427 ,  A61K31/445 ,  A61K31/4545 ,  A61K31/50 ,  A61K31/505 ,  A61K45/06 ,  C07B2200/07 ,  C07C229/14 ,  C07C229/48 ,  C07C229/50 ,  C07C2601/14 ,  C07C2602/44 ,  C07D205/04 ,  C07D207/16 ,  C07D209/44 ,  C07D211/34 ,  C07D211/46 ,  C07D213/38 ,  C07D213/65 ,  C07D215/14 ,  C07D237/14 ,  C07D239/34 ,  C07D249/06 ,  C07D277/28 ,  C07D401/04 ,  C07D401/10 ,  C07D417/04 ,  C07D417/06 ,  C07D487/04

摘要： Compounds of formula (I), and pharmaceutically acceptable salts thereof, can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).

摘要翻译： 式（I）化合物及其药学上可接受的盐可以调节一种或多种SIP受体的活性和/或自分泌素（ATX）的活性。

公开(公告)号：US20150252345A1

公开(公告)日：2015-09-10

申请号：US14430848

申请日：2013-09-25

申请人： BIOGEN IDEC MA INC.

发明人： Glenn Pierce ,  Samantha Truex ,  Robert T. Peters ,  Haiyan Jiang ,  Mark Brader

IPC分类号： C12N9/64

CPC分类号： C12N9/644 ,  A61K38/00 ,  C07K14/745 ,  C07K16/36 ,  C07K2317/76 ,  C07K2319/30 ,  C12Y304/21022

摘要： The present invention provides methods of administering long-acting Factor IX; methods of administering long-acting, chimeric and hybrid polypeptides comprising Factor IX; and methods of producing such chimeric and hybrid polypeptides using cells.

摘要翻译： 本发明提供了施用长效因子IX的方法; 施用包含因子IX的长效，嵌合和杂合多肽的方法; 以及使用细胞产生这种嵌合和杂交多肽的方法。

公开(公告)号：US20150210982A1

公开(公告)日：2015-07-30

申请号：US14563219

申请日：2014-12-08

申请人： Biogen Idec MA Inc.

发明人： Theodore J. YUN

IPC分类号： C12N5/0783 ,  G01N33/569

CPC分类号： C12N5/0637 ,  A61K2035/122 ,  A61K2039/5158 ,  C12N5/0636 ,  C12N2502/11 ,  G01N33/56972

摘要： The present invention provides a new method for isolating and enriching human regulatory T cells. The enriched cells are useful in the treatment of autoimmune disease.

公开(公告)号：US20150185235A1

公开(公告)日：2015-07-02

申请号：US14416214

申请日：2013-07-25

申请人： Biogen Idec MA Inc.

发明人： Jurg Sommer

IPC分类号： G01N33/86

CPC分类号： G01N33/86 ,  G01N33/92 ,  G01N2333/755 ,  G01N2333/9645 ,  G01N2800/224

摘要： The present disclosure provides methods and compositions for diagnosing and treating subject having a bleeding disorder. The disclosed methods comprise contacting a sample, e.g., a blood or plasma sample obtained from the patient, with an activation mixture comprising an activated coagulation factor and a phospholipid mixture, wherein the activation mixture is dried onto a solid substrate. Also provided is a global hemostasis test based on the integration of clotting time (Ct) and pharmacokinetics data. The methods and compositions presented can be applied to point-of-care diagnostic systems.

摘要翻译： 本公开提供了用于诊断和治疗出血性疾病的受试者的方法和组合物。 所公开的方法包括使样品例如从患者获得的血液或血浆样品与包含活化凝血因子和磷脂混合物的活化混合物接触，其中将活化混合物干燥至固体基质上。 还提供了基于凝血时间（Ct）和药代动力学数据的整合的全球止血试验。 所提出的方法和组合可以应用于护理点诊断系统。

公开(公告)号：US20150177240A1

公开(公告)日：2015-06-25

申请号：US14557653

申请日：2014-12-02

申请人： Biogen Idec MA Inc.

发明人： Sha Mi ,  John McCoy ,  R. Blake Pepinsky ,  Daniel H.S. Lee

IPC分类号： G01N33/569 ,  C12N5/0793

CPC分类号： G01N33/56966 ,  A61K38/00 ,  C07K14/4702 ,  C07K14/70571 ,  C07K16/18 ,  C07K16/2803 ,  C07K2319/30 ,  C12N5/0619 ,  C12N2500/46 ,  G01N33/5058 ,  G01N33/6896

摘要： The invention provides Sp35 polypeptides and fusion proteins thereof, Sp35 antibodies and antigen-binding fragments thereof and nucleic acids encoding the same. The invention also provides compositions comprising, and methods for making and using, such Sp35 antibodies, antigen-binding fragments thereof, Sp35 polypeptides and fusion proteins thereof.

摘要翻译： 本发明提供了Sp35多肽及其融合蛋白，Sp35抗体及其抗原结合片段和编码其的核酸。 本发明还提供了包含此类Sp35抗体，其抗原结合片段，Sp35多肽及其融合蛋白的制备和使用方法。

公开(公告)号：US20150168430A1

公开(公告)日：2015-06-18

申请号：US14402818

申请日：2013-05-22

申请人： Biogen Idec MA Inc.

发明人： Natalia Penner

IPC分类号： G01N33/94 ,  C07K5/062

CPC分类号： C07K5/0815 ,  C07K5/0215 ,  C07K5/0606 ,  C07K5/06086 ,  G01N33/6848 ,  G01N33/94 ,  Y02P20/55

摘要： The present invention provides compounds of Formula (I) and (II): (I) (II) wherein R1, R2, R4, R5, R6, X and n are as defined herein, and wherein R3 is hydrogen or a sulfur protecting group. Compounds of Formula (I) and (II), wherein R is hydrogen, may be useful in methods for detecting a reactive metabolite in a sample, e.g., wherein the metabolite is generated from the metabolism of a test compound, and wherein the metabolite and the compound of Formula (I) or (II) react to form a detectable adduct, e.g., detectable by mass spectrometry.

摘要翻译： 本发明提供式（I）和（II）的化合物：（I）（II）其中R 1，R 2，R 4，R 5，R 6，X和n如本文所定义，并且其中R 3是氢或硫保护基 。 式（I）和（II）的化合物，其中R是氢，可用于检测样品中的活性代谢物的方法，例如，其中代谢物是从测试化合物的代谢产生的，其中代谢物和 式（I）或（II）的化合物反应形成可检测的加合物，例如可通过质谱法检测。

公开(公告)号：US20150132259A1

公开(公告)日：2015-05-14

申请号：US14015711

申请日：2013-08-30

申请人： Biogen Idec MA Inc.

发明人： KoChung Lin ,  Blake Pepinsky ,  Ling Ling Chen ,  Donna M. Hess ,  Edward Y. Lin ,  Russell C. Petter ,  Darren P. Baker

IPC分类号： A61K38/21 ,  A61K47/48

CPC分类号： A61K47/48215 ,  A61K9/0019 ,  A61K38/215 ,  A61K45/06 ,  A61K47/60 ,  C07K14/565

摘要： The invention relates to novel polyalkylene glycol compounds and methods of using them. In particular, compounds comprising a novel polyethylene glycol conjugate are used alone, or in combination with antiviral agents to treat a viral infection, such as chronic hepatitis C.